CIK 0001980845 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
enGene Therapeutics Inc.
Sign in to watch- Ticker
- ENGN
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Oct 31
- Incorporated
- Canada (Federal Level)
- Entity type
- operating
- Phone
- (514) 332-4888
- Business address
- 4868 RUE LEVY, SUITE 220, SAINT-LAURENT, Quebec, Canada
- Former names
- enGene Holdings Inc.
Securities
- ENGN Common Stock Nasdaq
- ENGNW Warrants Nasdaq
- Open-market buys, last 90 days
- $10,051
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$10,051. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-22 | Grossman William Interim Chief Medical Officer | Purchase | +5,102 | $1.97 | $10K | 5,102 |
| 2026-06-16 | Astley-Sparke Philip Director | Grant or award · Stock Option (Right to Buy) | +31,000 | 31,000 | ||
| 2026-06-16 | BRUNK GERALD A Director | Grant or award · Stock Option (Right to Buy) | +31,000 | 31,000 | ||
| 2026-06-16 | Glickman Richard M Director | Grant or award · Stock Option (Right to Buy) | +31,000 | 31,000 | ||
| 2026-06-16 | Grossman William Interim Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +31,000 | 31,000 | ||
| 2026-06-16 | Grossman William Interim Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +200,000 | 200,000 | ||
| 2026-06-16 | HASTINGS PAUL J Director | Grant or award · Stock Option (Right to Buy) | +31,000 | 31,000 | ||
| 2026-06-16 | Heffernan Michael Thomas Director | Grant or award · Stock Option (Right to Buy) | +31,000 | 31,000 | ||
| 2026-06-16 | Joustra Wouter Director | Grant or award · Stock Option (Right to Buy) | +31,000 | 31,000 | ||
| 2026-06-16 | Zoth Lota S. Director | Grant or award · Stock Option (Right to Buy) | +31,000 | 31,000 | ||
| 2026-01-30 | CHEUNG ANTHONY TZEYEW Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +195,000 | 195,000 | ||
| 2026-01-30 | Giguere Lee Chief Legal Ofc. and Corp Secy | Grant or award · Stock Option (Right to Buy) | +195,000 | 195,000 | ||
| 2026-01-30 | Nichols Alexander Julian Chief Strategy & Ops. Ofc | Grant or award · Stock Option (Right to Buy) | +195,000 | 195,000 | ||
| 2026-01-30 | Daws D. Ryan Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +220,000 | 220,000 | ||
| 2026-01-30 | Cooper Ronald Harold Wilfred CEO & President | Grant or award · Stock Option (Right to Buy) | +801,000 | 801,000 | ||
| 2026-01-30 | Connolly Joan Chief Technology Officer | Grant or award · Stock Option (Right to Buy) | +195,000 | 195,000 | ||
| 2026-01-30 | Boyd Matthew Ross Chief Regulatory Officer | Grant or award · Stock Option (Right to Buy) | +195,000 | 195,000 | ||
| 2026-01-30 | Buck Jill Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +195,000 | 195,000 | ||
| 2025-09-30 | Sweiti Hussein Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +600,000 | 600,000 | ||
| 2025-07-08 | Boyd Matthew Ross Chief Regulatory Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 |
Page 1 of 6 · 120 trades